PMID- 24576654
OWN - NLM
STAT- MEDLINE
DCOM- 20140421
LR  - 20220410
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 41 Suppl 2
DP  - 2014 Feb
TI  - Management of sorafenib-related adverse events: a clinician's perspective.
PG  - S1-S16
LID - S0093-7754(14)00002-5 [pii]
LID - 10.1053/j.seminoncol.2014.01.001 [doi]
AB  - Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients 
      with unresectable hepatocellular carcinoma (HCC) and advanced renal cell 
      carcinoma (RCC). It is being evaluated in phase II and III clinical trials, which 
      include treatment as a single agent (locally advanced/metastatic radioactive 
      iodine-refractory differentiated thyroid cancer [DTC]), as part of multimodality 
      care (HCC), and in combination with chemotherapeutic agents (metastatic breast 
      cancer). Sorafenib-related adverse events (AEs) that commonly occur across these 
      tumor types include hand-foot skin reaction (HSFR), rash, upper and lower 
      gastrointestinal (GI) distress (ie, diarrhea), fatigue, and hypertension. These 
      commonly range from grade 1 to 3, per the Common Terminology Criteria for Adverse 
      Events (CTCAE), and often occur early in treatment. The goal for the management 
      of these AEs is to prevent, treat, and/or minimize their effects, thereby 
      enabling patients to remain on treatment and improve their quality of life. 
      Proactive management, along with ongoing patient education (before and during 
      sorafenib treatment), can help to effectively manage symptoms, often without the 
      need for sorafenib dose modification or drug holidays. Effective management 
      techniques for common sorafenib-related AEs, as well other important disease 
      sequelae not directly related to treatment, are presented. Recommendations and 
      observations are based on physician/author experience and recommendations from 
      published literature.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Brose, Marcia S
AU  - Brose MS
AD  - Assistant Professor, Director of the Thyroid Cancer Therapeutics Program, 
      Department of Otorhinolaryngology: Head and Neck Surgery, and the Division of 
      Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Frenette, Catherine T
AU  - Frenette CT
AD  - Medical Director of Liver Transplantation, Center for Organ and Cell 
      Transplantation, Scripps Clinic, San Diego, CA. Electronic address: 
      Frenette.Catherine@scrippshealth.org.
FAU - Keefe, Stephen M
AU  - Keefe SM
AD  - Assistant Professor, Division of Hematology/Oncology, Abramson Cancer Center, 
      University of Pennsylvania, Philadelphia, PA.
FAU - Stein, Stacey M
AU  - Stein SM
AD  - Assistant Professor of Medicine, Department of Medical Oncology, Yale School of 
      Medicine, New Haven, CT.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140109
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy
MH  - Carcinoma, Renal Cell/drug therapy
MH  - Disease Management
MH  - Fatigue/chemically induced/therapy
MH  - Gastrointestinal Diseases/chemically induced/therapy
MH  - Hand-Foot Syndrome/*etiology/therapy
MH  - Humans
MH  - Hypertension/*chemically induced/therapy
MH  - Kidney Neoplasms/drug therapy
MH  - Liver Neoplasms/drug therapy
MH  - Niacinamide/adverse effects/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*adverse effects/therapeutic use
MH  - Physicians
MH  - Sorafenib
EDAT- 2014/03/01 06:00
MHDA- 2014/04/22 06:00
CRDT- 2014/03/01 06:00
PHST- 2014/03/01 06:00 [entrez]
PHST- 2014/03/01 06:00 [pubmed]
PHST- 2014/04/22 06:00 [medline]
AID - S0093-7754(14)00002-5 [pii]
AID - 10.1053/j.seminoncol.2014.01.001 [doi]
PST - ppublish
SO  - Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. 
      Epub 2014 Jan 9.